State Board of Administration of Florida Retirement System Acquires New Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

State Board of Administration of Florida Retirement System acquired a new stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYAGet Rating) during the second quarter, HoldingsChannel reports. The institutional investor acquired 12,453 shares of the company’s stock, valued at approximately $172,000.

A number of other large investors have also made changes to their positions in the stock. Nisa Investment Advisors LLC purchased a new position in IDEAYA Biosciences during the second quarter worth about $25,000. Point72 Hong Kong Ltd lifted its position in IDEAYA Biosciences by 363.7% during the first quarter. Point72 Hong Kong Ltd now owns 3,376 shares of the company’s stock worth $38,000 after buying an additional 2,648 shares during the period. Quantbot Technologies LP lifted its position in IDEAYA Biosciences by 90.5% during the first quarter. Quantbot Technologies LP now owns 4,000 shares of the company’s stock worth $44,000 after buying an additional 1,900 shares during the period. Amalgamated Bank purchased a new position in IDEAYA Biosciences during the first quarter worth about $48,000. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its position in IDEAYA Biosciences by 12.7% during the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 10,416 shares of the company’s stock worth $117,000 after buying an additional 1,171 shares during the period. Institutional investors and hedge funds own 93.25% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on IDYA. Citigroup began coverage on IDEAYA Biosciences in a research report on Thursday, October 27th. They set a “buy” rating and a $26.00 target price on the stock. Oppenheimer increased their target price on IDEAYA Biosciences to $22.00 in a research report on Tuesday, September 6th. Guggenheim raised their price objective on IDEAYA Biosciences from $20.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, September 13th. Robert W. Baird raised their price objective on IDEAYA Biosciences from $18.00 to $24.00 and gave the stock an “outperform” rating in a report on Friday, November 18th. Finally, Stifel Nicolaus downgraded IDEAYA Biosciences from a “buy” rating to a “hold” rating and cut their price objective for the stock from $16.00 to $13.00 in a report on Monday, August 15th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, IDEAYA Biosciences currently has an average rating of “Moderate Buy” and a consensus price target of $28.14.

IDEAYA Biosciences Price Performance

IDEAYA Biosciences stock opened at $17.61 on Wednesday. The company has a market cap of $847.27 million, a price-to-earnings ratio of -12.95 and a beta of 0.99. IDEAYA Biosciences, Inc. has a 12 month low of $8.14 and a 12 month high of $24.66. The stock’s 50-day moving average is $15.52 and its 200-day moving average is $13.49.

IDEAYA Biosciences Profile

(Get Rating)

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations.

See Also

Want to see what other hedge funds are holding IDYA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEAYA Biosciences, Inc. (NASDAQ:IDYAGet Rating).

Institutional Ownership by Quarter for IDEAYA Biosciences (NASDAQ:IDYA)

Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.